Is Improved Survival a Class Effect of Angiotensin-Converting Enzyme Inhibitors?

Hennessy, Sean; Kimmel, Stephen E.

doi:10.7326/0003-4819-141-2-200407200-00016

Cited by 12 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who were prescribed antihypertensives other than ACEIs ( n = 420 074) were excluded because the focus of this analysis was CA ACEIs and non‐CA ACEIs (see Appendix Table 1 for list of ACEI classification). Non‐CA ACEI users were selected as the comparison group in this analysis because the CA properties of certain ACEIs have not been promoted and are not readily apparent to clinicians and many clinicians consider ACEIs to be an undifferentiated class of drug . Consequently, clinicians are unlikely to select an ACEI on the basis of its pharmacodynamic properties or the cognitive characteristics of the patient, which reduces the likelihood of selection bias or confounding by indication.…”

Section: Methodsmentioning

confidence: 99%

Time until incident dementia among Medicare beneficiaries using centrally acting or non‐centrally acting ACE inhibitors

Hebert

McBean

O’Connor

et al. 2013

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Time until incident dementia among Medicare beneficiaries using centrally acting or non‐centrally acting ACE inhibitors

Hebert

McBean

O’Connor

et al. 2013

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…The most robust CHF evidence lies with Ramipril/ Enalapril (ACE-I) and Candersartan/Valsartan (ARB). If the playing field was level the benefits are likely a "class effect" with minor variations [49][50][51]. Difference in glucose metabolism and IR favor ARB [26,49].…”

Section: Beta Blockersmentioning

confidence: 99%

Do We Need A Wider Therapeutic Paradigm For Heart Failure With Comorbidities?: A Remote Australian Perspective

Iyngkaran¹,

Thomas²

2016

Health Care: Current Reviews

View full text Add to dashboard Cite

Forty percent of CHF clients can suffer with up to five or more comorbidity, a rate that is likely higher in the NT. Large CHF trials AbstractCongestive Heart Failure a leading cause of morbidity and mortality is often associated with comorbidities and with it polypharmacy. Improved pathophysiological understanding, the available therapeutics, clinical guidelines and structured programs for comprehensive care have not benefited all clients in the Northern Territory of Australia. The Northern Territory has both a unique geography and demography including a sizeable Indigenous population. Additional factors that can affect heart failure management are prevalent in remote areas and are not well addressed within randomized controlled trials. This review is focused on building a case for widening the therapeutic paradigm for heart failure with comorbidities. We focus on a brief overview of heart failure and its associated comorbidities, the common overlapping physiological processes, the interpretation of the external validity of trial evidence, and finally exploring the available evidence for the important therapies within the guidelines. A need to consider a wider therapeutic paradigm may also have relevance for clients in other health systems.

show abstract

“…The extrapolation of the benefit of these drugs to their pharmacological families or other drugs or doses in the prevention of vascular disease recurrences following TIA or stroke, would be inappropriate [37, 107, 108]. …”

Section: Therapeutic Objectives Following Stroke: Analysis Of Currentmentioning

confidence: 99%

Blood Pressure as a Risk Factor for Stroke and the Impact of Antihypertensive Treatment

Gil‐Núñez¹,

Vivancos-Mora²

2005

Cerebrovasc Dis

View full text Add to dashboard Cite

We review hypertension and blood pressure levels as risk factors for stroke and the impact of antihypertensive treatment on the prevention of first stroke event and of recurrent stroke, not only with respect to the prevention of vascular events but also the prevention of cognitive deterioration, dementia, and physical disability. We review whether pharmacological blockage of the renin-angiotensin system has additional long-term effects over that of control of blood pressure levels alone, and the benefit of treatment with antihypertensive drugs in normotensive patients. Therapeutic objectives for blood pressure levels after stroke are defined together with recommendations of drugs and doses which have been demonstrated to have the greatest benefit in the prevention of stroke.

show abstract

Is Improved Survival a Class Effect of Angiotensin-Converting Enzyme Inhibitors?

Cited by 12 publications

References 6 publications

Time until incident dementia among Medicare beneficiaries using centrally acting or non‐centrally acting ACE inhibitors

Time until incident dementia among Medicare beneficiaries using centrally acting or non‐centrally acting ACE inhibitors

Do We Need A Wider Therapeutic Paradigm For Heart Failure With Comorbidities?: A Remote Australian Perspective

Blood Pressure as a Risk Factor for Stroke and the Impact of Antihypertensive Treatment

Contact Info

Product

Resources

About